Abstract
BackgroundPatients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma were treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC), initial clinical findings are presented.MethodsSingle institution, tertiary referral center certified for therapy of peritoneal disease. Prospective data collection of PIPAC therapy with doxorubicin 1.5 mg/m2 and cisplatin 7.5 mg/m2 of body surface delivered at intervals of six weeks. The outcome criteria were microscopic pathological response, survival and adverse events (v4.0 CTCAE).ResultsA total of 20 patients (m/f = 3:1) with a mean age of 64.9 (range: 45.0 to 87.0) years underwent 41 PIPAC procedures without intraoperative complications. The mean number of PIPAC cycles was 2.1 (range: one to four). Ten patients with ≥ 2 PIPAC applications were eligible for histological analysis to assess carcinoma regression. Complete or high grade tumor regression was found in two (10%) and five (25%) patients, respectively. An overall median survival of 36.6 weeks after the first PIPAC application was observed. One patient died postoperatively due to small bowel obstruction. No CTCAE level 3 and 4 complications occurred.ConclusionIn about one third of patients, repeated PIPAC therapy did induce histological regression of systemic chemo-resistant PC of pancreatic adenocarcinoma. Prospective randomized trials are needed to further clarify any clinical impact of such observations.
Highlights
The reported incidence of pancreatic adenocarcinoma (PAC) in western countries is increasing
Ten patients with ! 2 Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC) applications were eligible for histological analysis to assess carcinoma regression
Palliative systemic chemotherapy is considered the treatment of choice for peritoneal metastasized patients
Summary
The reported incidence of pancreatic adenocarcinoma (PAC) in western countries is increasing. While surgical resection remains the only possible curative option, local non-resectability and/or synchronous metastasis reduce eligibility of patients that undergo curative resection to less than 15% [2]. Even after complete surgical resection, 80% of patients will suffer from postoperative tumor recurrence within the first two years following surgery [3,4,5]. A frequent site of recurrence is the peritoneum, as 40% to 50% of cases show peritoneal metastasis [6]. Palliative systemic chemotherapy is considered the treatment of choice for peritoneal metastasized patients. Patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma were treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC), initial clinical findings are presented
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
